Please assess the completion status of the following clinical trial:

Trial Title: Enhancing Medication-based Analgesia in Humans- STUDY 2

Study Design Characteristics:
- Allocation: None
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: BASIC_SCIENCE
- Time Perspective: None
- Masking: TRIPLE
- Phase: PHASE2
- Number of Arms: 5.0

Eligibility Criteria:
Inclusion Criteria:~* Aged 18-75~* Urine sample tests negative for common illicit substances of abuse, including cannabis~* Medically cleared to take study medications~* Are not pregnant or breast feeding~* Willing to comply with the study protocol.~Exclusion Criteria:~* Meet DSM-5 criteria for alcohol/substance use disorder~* Taking opioids for pain~* Previous adverse reaction to a cannabinoid product~* Prescribed and taking stimulants or benzodiazepines~* Answer yes to item 1 of the Brief Pain Inventory indicating chronic pain~* Self-report any illicit drug or cannabinoid use in the past 7 days~* Presence of any clinically significant medical/psychiatric illness judged by the investigators to put subject at elevated risk for experiencing an adverse event~* History of seizure disorder~* Have a known allergy to the study medications or sesame seed oil~* ALT or AST levels \>3x ULN and/or Bilirubin levels \>2x ULN during Screening~* Current (past 60-day) suicidal thoughts or past year history of suicidal behavior~* Taking medications contraindicated with hydromorphone or cannabidiol~* Have a history of clinically significant cardiac arrhythmias or vasopastic disease~* Have an abnormal and clinically-significant ECG

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 75 Years
- Healthy Volunteers: t

Study Arms:
- Placebo+Placebo (Type: PLACEBO_COMPARATOR): Within-subject double-blind, double-dummy administration of placebo + placebo. Order of dose randomized session days 2-5.
- Hydromorphone+Placebo (Type: ACTIVE_COMPARATOR): Within-subject double-blind, double-dummy administration of hydromorphone (oral) 4mg + placebo. Always administered during session 1.
- Hydromorphone (oral) 4mg + Cannabidiol 50mg (Type: EXPERIMENTAL): Within-subject double-blind, double-dummy administration of hydromorphone (oral) 4mg + cannabidiol (oral) 50mg. Order of dose randomized session days 2-5.
- Hydromorphone (oral) 4mg + Cannabidiol 100mg (Type: EXPERIMENTAL): Within-subject double-blind, double-dummy administration of hydromorphone (oral) 4mg + cannabidiol (oral) 100mg. Order of dose randomized session days 2-5.
- Hydromorphone (oral) 4mg + Cannabidiol 200mg (Type: EXPERIMENTAL): Within-subject double-blind, double-dummy administration of hydromorphone (oral) 4mg + cannabidiol (oral) 200mg. Order of dose randomized session days 2-5.

Based on this trial design, predict the completion outcome and termination type (if applicable).